EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Disruption of protein–protein interaction hotspots in the C-terminal domain of MLH1 confers mismatch repair deficiency

Keri M Fishwick, Diego Gomez Vieito, Giada Greco, Giulio Collotta, Marco Gatti, Anastasija A Kulik, Raphaël Guérois iD, Ivan Corbeski, Ashutosh S Phadte, Issam Senoussi, Petr Cejka iD, Anna Pluciennik iD und 2 weitere

NAR Cancer · 2025

DOI: 10.1093/narcan/zcaf055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, 2025. Verfasst von Keri M Fishwick und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Cancer Research, University of Zurich, Strickhofstrasse 40a, CH-8057 Zurich, Switzerland. Hauptthemen laut MEDLINE: MutL Protein Homolog 1, DNA Mismatch Repair, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, NINDS NIH HHS, Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MutLα, a heterodimer of MLH1 and PMS2, plays a key role in DNA mismatch repair (MMR), which maintains genomic stability by correcting replication errors. Loss of MLH1 function causes MMR deficiency (MMRd), leading to elevated mutation rates and increased cancer susceptibility. However, MMRd can offer a therapeutic advantage, as high tumour mutational burden enhances the efficacy of immune checkpoint inhibition. MMR also drives somatic expansion of CAG repeats linked to Huntington’s disease (HD) pathogenesis. The C-terminal domain (CTD) of MLH1 contains at least two distinct protein–protein interaction (PPI) sites. The S1 site supports heterodimerization with the PMS2 endonuclease, whereas the S2 site interacts with MIP-boxes present in MMR-associated factors (EXO1, MSH3) and in the DNA repair nuclease FAN1. Here, using MLH1-S2 mutant cell models and synthetic FAN1-derived peptides containing two adjacent MLH1-binding motifs (MIP and MIM), we demonstrate that selective disruption of MLH1 PPIs impairs MMR in vitro. We further reveal that the peptide is able to inhibit the latent endonuclease activity of recombinant MutLα, possibly via competing with a putative MIM within PMS2. Our findings define key PPI interfaces within the MLH1(CTD) that govern MMR activity and may offer novel therapeutic opportunities to exploit MMRd in cancer and HD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutL Protein Homolog 1DNA Mismatch RepairNeoplastic Syndromes, HereditaryHumansMismatch Repair Endonuclease PMS2Protein BindingEndodeoxyribonucleasesProtein Interaction Domains and MotifsExodeoxyribonucleasesProtein DomainsMutationMultifunctional EnzymesBrain NeoplasmsColorectal Neoplasms

Substanzen

MutL Protein Homolog 1MLH1 protein, humanMismatch Repair Endonuclease PMS2FAN1 protein, humanEndodeoxyribonucleasesExodeoxyribonucleasesPMS2 protein, humanMultifunctional Enzymes

Autor:innen und Institutionen

  • Institute of Molecular Cancer Research, University of Zurich, Strickhofstrasse 40a, CH-8057 Zurich, Switzerland.
  • Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198 Gif-sur-Yvette, France.
  • Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
  • Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, United States.
  • Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Università della Svizzera Italiana (USI), CH-6500 Bellinzona, Switzerland.

ORCID-Profile: Raphaël Guérois, Petr Cejka, Anna Pluciennik, Alessandro A Sartori

Förderung

  • NIGMS NIH HHS
  • NINDS NIH HHS
  • Swiss National Science Foundation
  • Worldwide Cancer Research
  • Swiss Cancer Foundation
  • National Institutes of Health
  • Cejka laboratory
  • European Research Council

Zitieren

APA

Fishwick, K. M., Gomez Vieito, D., Greco, G., Collotta, G., Gatti, M., Kulik, A. A., Guérois, R., Corbeski, I., Phadte, A. S., Senoussi, I., Cejka, P., Pluciennik, A., Porro, A., & Sartori, A. A. (2025). Disruption of protein–protein interaction hotspots in the C-terminal domain of MLH1 confers mismatch repair deficiency. NAR Cancer. https://doi.org/10.1093/narcan/zcaf055

Vancouver

Fishwick KM, Gomez Vieito D, Greco G, Collotta G, Gatti M, Kulik AA, et al. Disruption of protein–protein interaction hotspots in the C-terminal domain of MLH1 confers mismatch repair deficiency. NAR Cancer. 2025. doi:10.1093/narcan/zcaf055

BibTeX
@article{Fishwick2025,
  author = {Fishwick, Keri M and Gomez Vieito, Diego and Greco, Giada and Collotta, Giulio and Gatti, Marco and Kulik, Anastasija A and Guérois, Raphaël and Corbeski, Ivan and Phadte, Ashutosh S and Senoussi, Issam and Cejka, Petr and Pluciennik, Anna and Porro, Antonio and Sartori, Alessandro A},
  title = {Disruption of protein–protein interaction hotspots in the C-terminal domain of MLH1 confers mismatch repair deficiency},
  journal = {NAR Cancer},
  year = {2025},
  doi = {10.1093/narcan/zcaf055}
}
Kostenlos starten →